Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional and Country Data (15 Countries) - Analysis and Forecast, 2021-2027

"Global Cell and Gene Therapy Market to Grow at a CAGR of 33.82% from 2021-2027."

Market Report Coverage - Cell and Gene Therapy

Market Segmentation

• By Product Type: Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-Cel, Zyntelego, Others

• By Therapeutic Class: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology and Other Therapeutic Classes

• By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Regional Segmentation

• North America - U.S., Canada

• Europe - Germany, France, Italy, U.K., Spain,The Netherlands, Russia, and Rest-of-Europe

• Asia-Pacific - China, Japan, India, Singapore, Australia, South Korea and Rest-of-Asia-Pacific (RoAPAC)

• Latin America - Brazil, Mexico, and Rest-of-the-Latin America

• Rest-of-the-World

Growth Drivers

• Increasing Incidences of Cancer and other Chronic Diseases

• Rising Number of Clinical Trials

• Increasing Funding and Investments in Cell and Gene Therapy Market

• Favorable Regulatory Environment and FDA Approvals for Cell and Gene Therapy Products

Market Challenges

• Lack of Reliable Vector Production for Cell and Gene Therapy

• Complex Manufacturing and Distribution Setup

• Tedious Process of Therapeutic Commercialization

Market Opportunities

• Drug Approvals and Strong Pipeline of Cell and Gene Therapies

• Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry

Key Cell and Gene Therapy Companies Profiled:

Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.

Key Questions Answered in this Report:

• What are the different types of approved cell and gene therapies available in the respective market?

• What are the key development strategies implemented by the key players to stand out in this market?

• What are the various manufacturing considerations within the cell and gene therapy market?

• How have the strategic collaborations among the key players providing a push to product development within the global cell and gene therapy market?

• What are the regulations pertaining to the global cell and gene therapy market in different regions?

• What are the initiatives implemented by different government bodies regulating the development and commercialization of cell and gene therapy products and associated platforms?

• How has COVID-19 impacted the cell and gene therapy market?

• How will the urgency of the pandemic influence the global cell and gene therapy market?

• What are the leading companies dominating the global cell and gene therapy market?

• What is the reimbursement scenario of the products offered in the global cell and gene therapy market?

• Based on the product type, which therapy in the global cell and gene therapy market is anticipated to witness a massive rise in demand in the forecast period?

• How is each segment of the global cell and gene therapy market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2027?

Market Overview

Cell and gene therapy are overlapping fields of biomedical research having similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim at modifying genetic material for treatment of a disease. Gene therapy uses genetic material, or DNA, to manipulate a patient's cells for the treatment of an inherited or acquired disease. Cell therapy is the introduction of new cells into a patient's body to grow, replace or repair damaged tissue to treat a disease. The cell and gene therapies are categorized into several therapeutic class, such as rare diseases, oncology, hematology, cardiovascular, ophthalmology, neurology, and others.

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is expected to grow at an impressive double-digit rate of 33.82% and reach a value of $25,002.1 million in 2027.

The existing cell and gene therapy market is favored by multiple factors, which include increasing incidences of cancer and other chronic diseases, rising number of clinical trials, increasing funding and investments in the cell and gene therapy market, and favorable regulatory environment and FDA Approvals for cell and gene therapy products.

Within the research report, the market is segmented on the basis of product type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), therapeutic class type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), and region (North America, Europe, Asia Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among other analyses, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

The global cell and gene therapy market witnessed 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions. 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions.

Major players within the cell and gene therapy market are: Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.

Table of Contents

1 Product Definition

• 1.1 Inclusion and Exclusion

2 Research Methodology

• 2.1 Primary Data Sources
• 2.2 Secondary Data Sources
• 2.3 Market Estimation Model
• 2.4 Selection Criteria for Company Profiles

3 Global Cell and Gene Therapy Market: Global Prospective

• 3.1 Introduction
• 3.2 Cell and Gene Therapy and Their Clinical Importance
• 3.3 Cell and Gene Therapy Development and Commercialization Landscape
• 3.4 Global Cell and Gene Therapy Market Size, 2020-2027
• 3.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
• 3.6 Reimbursement and Market Access
  • 3.6.1 Reimbursement Scenario of Cell and Gene Therapy Market, by Country
    • 3.6.1.1 U.S.
    • 3.6.1.2 EU 5
      • 3.6.1.2.1 France
      • 3.6.1.2.2 Germany
      • 3.6.1.2.3 Italy
      • 3.6.1.2.4 Spain
      • 3.6.1.2.5 U.K.
• 3.7 Key Companies in Cell and Gene Therapy Market and their Contributions

4 Market Overview

• 4.1 Cell and Gene Therapy Industry
• 4.2 Key Successful Cell and Gene Therapy Commercialization
  • 4.2.1 Regional Addressable Market and Growth Potential
• 4.3 North America
• 4.4 Europe
• 4.5 Asia-Pacific
• 4.6 Latin America
• 4.7 Rest-of-the-World

5 Impact of COVID-19 Pandemic on Global Cell and Gene Therapy Market

• 5.1 Disruption of Cell and Gene Therapy Market Due to COVID-19
• 5.2 COVID-19 Affecting Supply Chain of Cell and Gene Therapy Market
• 5.3 Interruption in Research and Clinical Development and Commercial Operation
  • 5.3.1 Research and Clinical Development
  • 5.3.2 Commercial Operation and Access
• 5.4 Navigating Crisis Recovery and Looking to the Future

6 Global Cell and Gene Therapy Market: Industry Analysis

• 6.1 Legal and Regulatory Framework and Requirements
  • 6.1.1 Overview of Regulatory Pathway for Cell and Gene Therapy
    • 6.1.1.1 Fast Track Designation:
    • 6.1.1.2 Breakthrough Therapy:
    • 6.1.1.3 Accelerated Approval:
    • 6.1.1.4 Priority Review:
    • 6.1.1.5 Regenerative Medicine Advanced Therapy Designation:
  • 6.1.2 Expedited Designation Vs. Traditional Approval Timelines:
  • 6.1.3 Regulatory Challenges
  • 6.1.4 Successful Regulatory Strategies

7 Patent Landscape

8 Cell and Gene Therapy Manufacturing

• 8.1 Viral Vector Manufacturing
  • 8.1.1 Retrovirus
  • 8.1.2 Lentivirus
  • 8.1.3 AAV
  • 8.1.4 Adenovirus
• 8.2 Upstream Manufacturing
  • 8.2.1 Cost Consideration and Timelines
  • 8.2.2 Process Design and Regulatory Burdens
  • 8.2.3 Other Considerations
• 8.3 Downstream Manufacturing
  • 8.3.1 Cost Considerations and Timelines
  • 8.3.2 Challenges in Downstream
  • 8.3.3 Scale-Up of Downstream from Research to Clinical Manufacturing
• 8.4 Non-Viral Vector Manufacturing
  • 8.4.1 Non-Viral, Plasmid-Free Manufacturing
  • 8.4.2 Plasmid
  • 8.4.3 Naked DNA
  • 8.4.4 Physical-Mediated Methods
• 8.5 Cell and Gene Therapy Manufacturing Capacity, by Company

9 Global Cell and Gene Therapy Market: Market Dynamics

• 9.1 Overview
• 9.2 Market Drivers
  • 9.2.1 Increasing Incidences of Cancer and Other Chronic Diseases
  • 9.2.2 High Number of Rare Diseases Across Globe
  • 9.2.3 Rising Number of Clinical Trials
  • 9.2.4 Increasing Funding and Investments in Cell and Gene Therapy Market
  • 9.2.5 Favorable Regulatory Environment for Cell and Gene Therapy Products
• 9.3 Market Restrains
  • 9.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
  • 9.3.2 Complex Manufacturing and Distribution Setup
  • 9.3.3 Tedious Process of Therapeutic Commercialization
• 9.4 Market Opportunities
  • 9.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
  • 9.4.2 Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry

10 Global Cell and Gene Therapy Market: Competitive Landscape

• 10.1 Key Strategies and Development
  • 10.1.1 Product Offerings and Approvals
• 10.2 Synergistic Activities
• 10.3 Funding and Business Expansions
• 10.4 Mergers and Acquisitions
• 10.5 Market Share Analysis
• 10.6 Growth-Share Analysis (by Company), 2020

11 Global Cell and Gene Therapy Market (by Product)

• 11.1 Therapeutic Market
  • 11.1.1 Yescarta
  • 11.1.2 Provenge
  • 11.1.3 Luxturna
  • 11.1.4 Kymriah
  • 11.1.5 Imlygic
  • 11.1.6 Gintuit
  • 11.1.7 MACI
  • 11.1.8 Gendicine
  • 11.1.9 Oncorine
  • 11.1.10 Neovasculgen
  • 11.1.11 Strimvelis
  • 11.1.12 Invossa
  • 11.1.13 Zolgensma
  • 11.1.14 Tecartus
  • 11.1.15 Liso-Cel
  • 11.1.16 Zyntelego
  • 11.1.17 Others
• 11.2 Pipeline Analysis
  • 11.2.1 Phase 1
  • 11.2.2 Phase 2
  • 11.2.3 Phase 3
    • 11.2.3.1 SPK-8011
    • 11.2.3.2 OTL-103
    • 11.2.3.3 OTL-200
    • 11.2.3.4 OTL-101
    • 11.2.3.5 VM202
    • 11.2.3.6 GS010
    • 11.2.3.7 bb2121
    • 11.2.3.8 PTC-AADC
  • 11.2.4 Pipeline Analysis - CAR-T Focused
  • 11.2.5 Pipeline Analysis - CAR-NK Focused

12 Global Cell and Gene Therapy Market (by Therapeutic Class)

• 12.1 Overview
• 12.2 Rare Diseases
• 12.3 Oncology
• 12.4 Hematology
• 12.5 Cardiovascular
• 12.6 Ophthalmology
• 12.7 Neurology
• 12.8 Other Therapeutic Classes

13 Global Cell and Gene Therapy Market (by Region)

• 13.1 Overview
• 13.2 North America
  • 13.2.1 U.S.
    • 13.2.1.1 Approved Products
    • 13.2.1.2 Competitive Landscape
    • 13.2.1.3 Market Size and Forecast
    • 13.2.1.4 Key Developments
  • 13.2.2 Canada
    • 13.2.2.1 Approved Products
    • 13.2.2.2 Market Size and Forecast
    • 13.2.2.3 Key Developments
• 13.3 Europe
  • 13.3.1 Europe Cell and Gene Therapy Market Dynamics
  • 13.3.2 Germany
    • 13.3.2.1 Approved Products
    • 13.3.2.2 Market Size and Forecast
    • 13.3.2.3 Key Developments
  • 13.3.3 France
    • 13.3.3.1 Approved Products
    • 13.3.3.2 Market Size and Forecast
    • 13.3.3.3 Key Developments
    • 13.3.3.4 Competitive Landscape
  • 13.3.4 U.K.
    • 13.3.4.1 Approved Products
    • 13.3.4.2 Market Size and Forecast
    • 13.3.4.3 Competitive Landscape
  • 13.3.5 Italy
    • 13.3.5.1 Approved Products
    • 13.3.5.2 Market Size and Forecast
    • 13.3.5.3 Key Developments
  • 13.3.6 Spain
    • 13.3.6.1 Approved Products
    • 13.3.6.2 Market Size and Forecast
    • 13.3.6.3 Key Developments
    • 13.3.6.4 Competitive Landscape
  • 13.3.7 The Netherlands
    • 13.3.7.1 Approved Products
    • 13.3.7.2 Market Size and Forecast
    • 13.3.7.3 Key Developments
    • 13.3.7.4 Competitive Landscape
  • 13.3.8 Russia
    • 13.3.8.1 Approved Products
    • 13.3.8.2 Market Size and Forecast
    • 13.3.8.3 Competitive Landscape
  • 13.3.9 Rest-of-Europe
    • 13.3.9.1 Market Size and Forecast
    • 13.3.9.2 Key Developments
• 13.4 Asia-Pacific (APAC)
  • 13.4.1 Japan
    • 13.4.1.1 Approved Products
    • 13.4.1.2 Market Size and Forecast
    • 13.4.1.3 Key Developments
    • 13.4.1.4 Competitive Landscape
  • 13.4.2 China
    • 13.4.2.1 Approved Products
    • 13.4.2.2 Market Size and Forecast
    • 13.4.2.3 Key Developments
    • 13.4.2.4 Competitive Landscape
  • 13.4.3 Australia
    • 13.4.3.1 Approved Products
    • 13.4.3.2 Market Size and Forecast
    • 13.4.3.3 Key Developments
  • 13.4.4 South Korea
    • 13.4.4.1 Approved Products
    • 13.4.4.2 Market Size and Forecast
    • 13.4.4.3 Key Developments
    • 13.4.4.4 Competitive Landscape
  • 13.4.5 India
    • 13.4.5.1 Approved Products
    • 13.4.5.2 Market Size and Forecast
    • 13.4.5.3 Competitive Landscape
  • 13.4.6 Singapore
    • 13.4.6.1 Approved Products
    • 13.4.6.2 Market Size and Forecast
    • 13.4.6.3 Key Developments
  • 13.4.7 Rest-of-Asia-Pacific
    • 13.4.7.1 Market Size and Forecast
    • 13.4.7.2 Key Developments
• 13.5 Latin America
  • 13.5.1 Brazil
    • 13.5.1.1 Market Size and Forecast
  • 13.5.2 Mexico
    • 13.5.2.1 Market Size and Forecast
  • 13.5.3 Rest-of-Latin America (RoLA)
    • 13.5.3.1 Market Size and Forecast
• 13.6 Rest-of-World
  • 13.6.1 Market Size and Forecast

14 Company Profile

• 14.1 Amgen Inc.
  • 14.1.1 Company Overview
  • 14.1.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market
  • 14.1.3 Financials
  • 14.1.4 Key Insights About Financial Health of the Company
  • 14.1.5 SWOT Analysis
• 14.2 bluebird bio, Inc.
  • 14.2.1 Company Overview
  • 14.2.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
  • 14.2.3 Financials
  • 14.2.4 Key Insights About Financial Health of the Company
  • 14.2.5 SWOT Analysis
• 14.3 Dendreon Pharmaceuticals LLC.
  • 14.3.1 Company Overview
  • 14.3.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Market
  • 14.3.3 SWOT Analysis
• 14.4 Castle Creek Pharmaceutical Holdings
  • 14.4.1 Company Overview
  • 14.4.2 Role of Castle Creek Pharmaceutical Holdings in the Global Cell and Gene Therapy Market
  • 14.4.3 SWOT Analysis
• 14.5 Human Stem Cells Institute
  • 14.5.1 Company Overview
  • 14.5.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
  • 14.5.3 SWOT Analysis
• 14.6 Kite Pharma, Inc.
  • 14.6.1 Company Overview
  • 14.6.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
  • 14.6.3 Financials
  • 14.6.4 Key Insights About Financial Health of the Company
  • 14.6.5 SWOT Analysis
• 14.7 Kolon TissueGene, Inc.
  • 14.7.1 Company Overview
  • 14.7.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
  • 14.7.3 SWOT Analysis
• 14.8 Novartis AG
  • 14.8.1 Company Overview
  • 14.8.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
  • 14.8.3 Financials
  • 14.8.4 Key Insights About Financial Health of the Company
  • 14.8.5 SWOT Analysis
• 14.9 Orchard Therapeutics plc.
  • 14.9.1 Company Overview
  • 14.9.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Market
  • 14.9.3 Financials
  • 14.9.4 SWOT Analysis
• 14.10 Organogenesis Holdings Inc.
  • 14.10.1 Company Overview
  • 14.10.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
  • 14.10.3 Financials
  • 14.10.4 Key Insights About Financial Health of the Company
  • 14.10.5 SWOT Analysis
• 14.11 Pfizer, Inc.
  • 14.11.1 Company Overview
  • 14.11.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
  • 14.11.3 Financials
  • 14.11.4 Key Insights About Financial Health of the Company
  • 14.11.5 SWOT Analysis
• 14.12 RENOVA THERAPEUTICS
  • 14.12.1 Company Overview
  • 14.12.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
  • 14.12.3 SWOT Analysis
• 14.13 Shanghai Sunway Biotech Co., Ltd.,
  • 14.13.1 Company Overview
  • 14.13.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
  • 14.13.3 SWOT Analysis
• 14.14 Sibiono GeneTech Co. Ltd.,
  • 14.14.1 Company Overview
  • 14.14.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy
  • 14.14.3 SWOT Analysis
• 14.15 Spark Therapeutics, Inc.
  • 14.15.1 Company Overview
  • 14.15.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
  • 14.15.3 Financials
  • 14.15.4 Key Insights About Financial Health of the Company
  • 14.15.5 SWOT Analysis
• 14.16 Vericel Corporation
  • 14.16.1 Company Overview
  • 14.16.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
  • 14.16.3 Financials
  • 14.16.4 Key Insights About Financial Health of the Company
  • 14.16.5 SWOT Analysis

List of Tables

• Table 3.1: Approved Gene Therapies Worldwide
• Table 3.2: Key Companies in Cell and Gene Therapy Market, 2020
• Table 4.1: Key Products of Cell and Gene Therapy Market
• Table 8.1: Key Viral Vectors
• Table 8.2: Cell and Gene Therapy Manufacturing Capacity (by Company)
• Table 9.1: Number of Clinical Trials for Cell and Gene Therapy, 2020
• Table 11.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)
• Table 11.2: Key Cell and Gene Therapy Drugs in Phase 3, 2020
• Table 12.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA

List of Figures

• Figure 1: Cell and Gene Therapy Funding (2019 and 2020-H1)
• Figure 2: Global Cell and Gene Therapy Market, 2020-2027
• Figure 3: Market Drivers, Opportunities, and Restraints
• Figure 4: Share of Key Developments and Strategies, January 2016-January 2021
• Figure 5: Global Cell and Gene Therapy Market Share (Product Type), 2020-2027
• Figure 6: Global Cell and Gene Therapy Market Share (by Therapeutic Class), 2020-2027
• Figure 7: Global Cell and Gene Therapy Market (by Region)
• Figure 1.1: Definitions of Cell and Gene Therapies
• Figure 2.1: Global Cell and Gene Therapy Market Research Methodology
• Figure 2.2: Primary Research Methodology
• Figure 2.3: Global Cell and Gene Therapy Market Research Methodology Approach
• Figure 2.4: Total Number of Companies Profiled
• Figure 3.1: Clinical Trials by Therapeutic Category, Regenerative Medicines and Advanced Therapies, 2020
• Figure 3.2: Global Cell and Gene Therapy Market Size, 2020-2027
• Figure 3.3: Factors Involved in Payer Decision Flow, Process Considerations and Stakeholder Drivers in Reimbursement in U.S.
• Figure 3.4: Emerging Payment Models for Cell and Gene Therapies in Europe
• Figure 4.1: Addressable Market Size of Commercialized Products, 2020
• Figure 4.2: Global Cell and Gene Therapy Market, 2020-2027
• Figure 4.3: North America Cell and Gene Therapy Addressable Market, 2020 Vs 2027
• Figure 4.4: Europe Cell and Gene Therapy Addressable Market, 2020 Vs 2027
• Figure 4.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2020 Vs 2027
• Figure 4.6: Latin America Cell and Gene Therapy Addressable Market 2020 Vs 2027
• Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
• Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Cell and Gene Therapy Market, 2020-2025
• Figure 5.3: Areas of Disruption in Clinical Development
• Figure 5.4: Measure to Navigate Crisis Recovery
• Figure 6.1: Expedited Approval Designations for Cell and Gene Therapies
• Figure 7.1: Number of Patents (by Year), 2016-2020
• Figure 7.2: Share of Patents (by Country), 2016-2021
• Figure 8.1: Steps Involved in Bioprocessing
• Figure 8.2: Typical Production Methods of Viral Vectors
• Figure 8.3: Typical Production Method of Plasmid Vectors
• Figure 9.1: Impact Analysis of Market Dynamics
• Figure 9.2: Rising Incidences of Cancer (2015 and 2018)
• Figure 9.3: Prevalence of Rare Diseases
• Figure 9.4: Deal Value of Mergers and Acquisitions (2016-2019)
• Figure 10.1: Share of Key Developments and Strategies, January 2016- January 2021
• Figure 10.2: Share of Product Offerings and Approvals, January 2016-January 2021
• Figure 10.3: Share of Synergistic Activities, January 2016-January 2021
• Figure 10.4: Share of Funding and Expansions, January 2016-January 2021
• Figure 10.5: Share of Mergers and Acquisitions, January 2016-January 2021
• Figure 10.6: Market Share Analysis: Global Cell and Gene Therapy Market, 2020
• Figure 10.7: Growth-Share Matrix for Global Cell and Gene Therapy Market (by Company), 2020
• Figure 11.1: Global Cell and Gene Therapy Market (by Therapeutic Drugs), 2020-2027
• Figure 11.2: Global Revenue for Yescarta, 2020-2027
• Figure 11.3: Global Revenue for Provenge, 2020-2027
• Figure 11.4: Global Revenue for Luxturna, 2020-2027
• Figure 11.5: Global Revenue for Kymriah, 2020-2027
• Figure 11.6: Global Revenue for Imlygic, 2020-2027
• Figure 11.7: Global Revenue for MACI, 2020-2027
• Figure 11.8: Global Revenue for Gendicine, 2020-2027
• Figure 11.9: Global Revenue for Oncorine, 2020-2027
• Figure 11.10: Global Revenue for Neovasculogen, 2020-2027
• Figure 11.11: Global Revenue for Strimvelis, 2020-2027
• Figure 11.12: Global Revenue for Invossa, 2020-2027
• Figure 11.13: Global Revenue for Zolgensma, 2020-2027
• Figure 11.14: Global Revenue for Tecartus, 2020-2027
• Figure 11.15: Global Revenue for Other Drugs, 2020-2027
• Figure 11.16: Global Revenue for Other Drugs, 2020-2027
• Figure 11.17: Global Revenue for Other Drugs, 2020-2027
• Figure 11.18: Cell and Gene Therapy Medicines in Development by Disease, 2018
• Figure 11.19: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2018-2020
• Figure 11.20: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2018-2020
• Figure 11.21: Global Cell and Gene Therapy Market, by Late Phase, 2021-2027
• Figure 11.22: Global Revenue for SPK-8011, 2020-2027
• Figure 11.23: Global Revenue for OTL-103, 2021-2027
• Figure 11.24: Global Revenue for OTL-200, 2020-2027
• Figure 11.25: Global Revenue for OTL-101, 2021-2027
• Figure 11.26: Global Revenue for VM 202, 2021-2027
• Figure 11.27: Global Revenue for GS010, 2021-2027
• Figure 11.28: Global Revenue for bb2121, 2021-2027
• Figure 11.29: Global Revenue for PTC-AADC, 2021-2027
• Figure 11.30: Pipeline For CAR-T Therapies (2020)
• Figure 12.1: Global Cell and Gene Therapy Market (Rare Diseases), 2020-2027
• Figure 12.2: Global Cell and Gene Therapy Market (Oncology), 2020-2027
• Figure 12.3: Global Cell and Gene Therapy Market (Hematology), 2020-2027
• Figure 12.4: Global Cell and Gene Therapy Market (Cardiovascular Disease), 2020-2027
• Figure 12.5: Global Cell and Gene Therapy Market (Ophthalmology), 2020-2027
• Figure 12.6: Global Cell and Gene Therapy Market (Neurology), 2020-2027
• Figure 12.7: Global Cell and Gene Therapy Market (Other Therapeutic Class), 2020-2027
• Figure 12.8: Global Cell and Gene Therapy Market (by Region)
• Figure 12.9: North America Global Cell and Gene Therapy Market, 2020-2027
• Figure 12.10: North America: Market Dynamics
• Figure 12.11: U.S. Cell and Gene Therapy Market, 2020-2027
• Figure 12.12: Canada Cell and Gene Therapy Market, 2020-2027
• Figure 12.13: Europe Cell and Gene Therapy Market, 2020-2027
• Figure 12.14: Europe: Market Dynamics
• Figure 12.15: Germany Cell and Gene Therapy Market, 2020-2027
• Figure 12.16: France Cell and Gene Therapy Market, 2020-2027
• Figure 12.17: U.K. Cell and Gene Therapy Market, 2020-2027
• Figure 12.18: Italy Cell and Gene Therapy Market, 2020-2027
• Figure 12.19: Spain Cell and Gene Therapy Market, 2020-2027
• Figure 12.20 Netherlands Cell and Gene Therapy Market, 2020-2027
• Figure 12.21: Russia Cell and Gene Therapy Market, 2020-2027
• Figure 12.22: Rest-of-Europe Cell and Gene Therapy Market, 2020-2027
• Figure 12.23: Asia-Pacific Cell and Gene Therapy Market, 2020-2027
• Figure 12.24: Asia-Pacific Market Dynamics
• Figure 12.25: Japan Cell and Gene Therapy Market, 2020-2027
• Figure 12.26: China Cell and Gene Therapy Market, 2020-2027
• Figure 12.27: Australia Cell and Gene Therapy Market, 2020-2027
• Figure 12.28: South Korea Cell and Gene Therapy Market, 2020-2027
• Figure 12.29: India Cell and Gene Therapy Market, 2020-2027
• Figure 12.30: Singapore Cell and Gene Therapy Market, 2020-2027
• Figure 12.31: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2020-2027
• Figure 12.32: Latin America Cell and Gene Therapy Market, 2020-2027
• Figure 12.33: Latin America: Market Dynamics
• Figure 12.34: Brazil Cell and Gene Therapy Market, 2020-2027
• Figure 12.35: Mexico Cell and Gene Therapy Market, 2020-2027
• Figure 12.36: Rest-of-Latin America Cell and Gene Therapy Market, 2020-2027
• Figure 12.37: Rest-of-World Cell and Gene Therapy Market, 2020-2027
• Figure 13.1: Amgen Inc.: Overall Product Portfolio
• Figure 13.2: Amgen Inc.: Pipeline Product Portfolio
• Figure 13.3: Amgen Inc.: Overall Financials, 2017-2019
• Figure 13.4: Amgen Inc.: Revenue (by Region), 2017-2019
• Figure 13.5: Amgen Inc.: R&D Expenditure, 2017-2019
• Figure 13.6: Amgen Inc.: SWOT Analysis
• Figure 13.7: Pipeline Product Portfolio: bluebird bio, Inc.
• Figure 13.8: bluebird bio, Inc.: Overall Financials, 2017-2019
• Figure 13.9: bluebird bio, Inc.: R&D Expenditure, 2017-2019
• Figure 13.10: bluebird bio, Inc.: SWOT Analysis
• Figure 13.11: Dendreon Pharmaceuticals LLC: Product Portfolio
• Figure 13.12: Dendreon Pharmaceuticals LLC.: SWOT Analysis
• Figure 13.13: Castle Creek Pharmaceutical Holdings: Overall Product Portfolio
• Figure 13.14: Castle Creek Pharmaceutical Holdings : Pipeline Product Portfolio
• Figure 13.15: Castle Creek Pharmaceutical: SWOT Analysis
• Figure 13.16: Human Stem Cell Institute: Overall Product Portfolio
• Figure 13.17: Human Stem Cell Institute: SWOT Analysis
• Figure 13.18: Kite Pharma, Inc.: Overall Product Portfolio
• Figure 13.19: Kite Pharma, Inc.: Pipeline Product Portfolio
• Figure 13.20: Kite Pharma, Inc.: Overall Financials, 2016-2018
• Figure 13.21: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
• Figure 13.22: Kite Pharma, Inc.: SWOT Analysis
• Figure 13.23: Kolon TissueGene, Inc.: Pipeline Product Portfolio
• Figure 13.24: Kolon TissueGene, Inc.: SWOT Analysis
• Figure 13.25: Novartis AG: Overall Product Portfolio
• Figure 13.26: Novartis AG: Pipeline Product Portfolio
• Figure 13.27: Novartis AG: Overall Financials, 2017-2019
• Figure 13.28: Novartis AG: Revenue (by Business Segment), 2017-2019
• Figure 13.29: Novartis AG: Net Revenue (by Region), 2017-2019
• Figure 13.30: Novartis AG: R& D Expense, 2017-2019
• Figure 13.31: Novartis AG: SWOT Analysis
• Figure 13.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
• Figure 13.33: Orchard Therapeutics plc.: Overall Financials, 2017-2019
• Figure 13.34: Orchard Therapeutics plc: SWOT Analysis
• Figure 13.35: Organogenesis Holdings Inc.: Overall Product Portfolio
• Figure 13.36: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
• Figure 13.37: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
• Figure 13.38: Organogenesis Holdings Inc.: SWOT Analysis
• Figure 13.39: Pfizer, Inc.: Overall Product Portfolio
• Figure 13.40: Pfizer, Inc.: Pipeline Product Portfolio
• Figure 13.41: Pfizer, Inc.: Overall Financials, 2017-2019
• Figure 13.42: Pfizer, Inc.: Revenue (by Region), 2017-2019
• Figure 13.43: Pfizer, Inc.: R&D Expenditure, 2017-2019
• Figure 13.44: Pfizer, Inc.: SWOT Analysis
• Figure 13.45: RENOVA THERAPEUTICS: Pipeline Product Portfolio
• Figure 13.46: RENOVA THERAPEUTICS: SWOT Analysis
• Figure 13.47: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
• Figure 13.48: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
• Figure 13.49: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
• Figure 13.50: Sibiono GeneTech Co. Ltd.: SWOT Analysis
• Figure 13.51: Spark Therapeutics, Inc.: Overall Product Portfolio
• Figure 13.52: Spark Therapeutics, Inc.: Pipeline Product Portfolio
• Figure 13.53: Spark Therapeutics, Inc.: Overall Financials, 2017-2019
• Figure 13.54: Spark Therapeutics, Inc.: R&D Expenditure, 2017-2019
• Figure 13.55: Spark Therapeutics, Inc.: SWOT Analysis
• Figure 13.56: Vericel Corporation: Overall Product Portfolio
• Figure 13.57: Vericel Corporation: Overall Financials, 2017-2019
• Figure 13.58: Vericel Corporation: Revenue (by Product), 2017-2019
• Figure 13.59: Vericel Corporation: R&D Expenditure (2017-2019)
• Figure 13.60: Vericel Corporation: SWOT Analysis